Meyka Pro banner
BrainsWay Ltd.

BrainsWay Ltd. Fundamental Analysis (NASDAQ: BWAY)

BWAYNASDAQ
HealthcareMedical - Devices
$14.74
$0.43(2.83%)
U.S. Market opens in 63h 23m

BrainsWay Ltd. Fundamental Analysis (NASDAQ: BWAY)

BrainsWay Ltd. (NASDAQ: BWAY) shows moderate financial fundamentals with a PE ratio of 32.21, profit margin of 15.65%, and ROE of 12.80%. The company generates $0.1B in annual revenue with strong year-over-year growth of 37.83%.

Key Strengths

Cash Position20.76%
PEG Ratio0.17
Current Ratio3.59

Areas of Concern

No major concerns flagged.
We analyze BWAY's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 74.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
74.1/100

We analyze BWAY's fundamental strength across five key dimensions:

Efficiency Score

Weak

BWAY struggles to generate sufficient returns from assets.

ROA > 10%
7.83%

Valuation Score

Moderate

BWAY shows balanced valuation metrics.

PE < 25
32.21
PEG Ratio < 2
0.17

Growth Score

Moderate

BWAY shows steady but slowing expansion.

Revenue Growth > 5%
37.83%
EPS Growth > 10%
1.56%

Financial Health Score

Excellent

BWAY maintains a strong and stable balance sheet.

Debt/Equity < 1
0.09
Current Ratio > 1
3.59

Profitability Score

Moderate

BWAY maintains healthy but balanced margins.

ROE > 15%
12.80%
Net Margin ≥ 15%
15.65%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BWAY Expensive or Cheap?

P/E Ratio

BWAY trades at 32.21 times earnings. This suggests a premium valuation.

32.21

PEG Ratio

When adjusting for growth, BWAY's PEG of 0.17 indicates potential undervaluation.

0.17

Price to Book

The market values BrainsWay Ltd. at 3.74 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.74

EV/EBITDA

Enterprise value stands at 52.07 times EBITDA. This signals the market has high growth expectations.

52.07

How Well Does BWAY Make Money?

Net Profit Margin

For every $100 in sales, BrainsWay Ltd. keeps $15.65 as profit after all expenses.

15.65%

Operating Margin

Core operations generate 12.47 in profit for every $100 in revenue, before interest and taxes.

12.47%

ROE

Management delivers $12.80 in profit for every $100 of shareholder equity.

12.80%

ROA

BrainsWay Ltd. generates $7.83 in profit for every $100 in assets, demonstrating efficient asset deployment.

7.83%

Following the Money - Real Cash Generation

Operating Cash Flow

BrainsWay Ltd. produces operating cash flow of $15.95M, showing steady but balanced cash generation.

$15.95M

Free Cash Flow

BrainsWay Ltd. produces free cash flow of $11.12M, offering steady but limited capital for shareholder returns and expansion.

$11.12M

FCF Per Share

Each share generates $0.28 in free cash annually.

$0.28

FCF Yield

BWAY converts 0.99% of its market value into free cash.

0.99%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

32.21

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.17

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.74

vs 25 benchmark

P/S Ratio

Price to sales ratio

9.50

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.09

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.59

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.13

vs 25 benchmark

ROA

Return on assets percentage

0.08

vs 25 benchmark

ROCE

Return on capital employed

0.08

vs 25 benchmark

How BWAY Stacks Against Its Sector Peers

MetricBWAY ValueSector AveragePerformance
P/E Ratio32.2130.97 Neutral
ROE12.80%515.00% Weak
Net Margin15.65%30203.00% Weak
Debt/Equity0.090.53 Strong (Low Leverage)
Current Ratio3.595.71 Strong Liquidity
ROA7.83%-15.00% (disorted) Weak

BWAY outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BrainsWay Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

50.67%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

190.20%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

837.69%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ